What Zydex does

Zydex Limited is a privately held UK pharmaceutical broker that facilitates the import and export of pharmaceutical products for healthcare-sector organisations and related industries in the UK and internationally. The company sits between global pharmaceutical manufacturers/suppliers and buyers, generating revenue through transaction-based fees on pharmaceutical trades. It is incorporated as a private limited company in the United Kingdom and operates without a disclosed parent entity, institutional investors, funding history, or capital structure information.

The company's marketed portfolio comprises ten branded pharmaceutical products sourced from third-party manufacturers and spanning multiple therapeutic categories: Pseudovac (polyvalent vaccine for Pseudomonas aeruginosa infections), Fluvaxin (influenza prevention for workplace wellness), Rovatinex (urolithiasis treatment), Akineton/Biperiden (Parkinson's disease treatment), FATOL Riemser anti-tuberculosis drugs, Provag (peroral probiotic for vaginal dysbacteriosis), SiderAl (iron-deficient anemia treatment, ranked first in iron-bearing drug sales in Italy), Gestalis (prenatal multivitamins with vitamin K, selenium, liposome iron, and algal DHA), Dapson Fatol (autoimmune disease treatment), and DiCappa (osteoporosis prevention combining vitamins K2 and D3, listed as forthcoming). The underlying technology is described as a pharmaceutical brokering and international trade facilitation platform, with no proprietary technical components, patents, trademarks, or certifications disclosed.

Zydex's go-to-market is sales-led and relationship-driven, with self-reported 20-plus years of sector experience and an extensive network of global manufacturers and suppliers spanning Europe to Asia. Distribution is direct enterprise supply to healthcare organisations; marketing channels are limited to a website contact form and direct phone/email contact. Pricing is quote-based and not publicly disclosed. The company maintains two UK locations — headquarters at 42-44 Bishopsgate in the City of London financial district and an operational office in Slough — and operates with 11–50 employees. No named customers, certifications, regulatory actions, partnerships, or named management team are disclosed in the available data.

Name

Zydex

Legal name

Zydex Limited

Website

https://zydex.co.uk

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Zydex Limited is a UK-based pharmaceutical broker that facilitates import and export of branded medicines, vaccines, and medical products for healthcare-sector organisations across European and Asian markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Brokering

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Wholesale Trade Agents and Brokers (42512)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Parallel Import/Export & Secondary Market Pharmaceutical Wholesalers (HLAIAJAK)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical brokering
• Pharmaceutical import export
• Pharmaceutical wholesale
• Medical supplies sourcing
• Pharmaceutical distribution services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Brokering Services: The company facilitates import and export of pharmaceutical supplies, brokering deals between buyers and suppliers in the healthcare sector. Revenue is generated through transaction-based fees on pharmaceutical product trades.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Zydex Limited brokers the import and export of pharmaceutical products, sourcing branded medicines, vaccines, and medical products from a global network of manufacturers and suppliers and supplying them to healthcare sector organisations and related industries in the UK and international markets (Europe to Asia). The company operates a relationship-driven brokerage model with quote-based pricing, credit lines, and discount structures available to patrons.

Product overview

Zydex Limited is a pharmaceutical broker specializing in the import and export of pharmaceutical products for the UK and international markets. The company offers a portfolio of branded pharmaceutical products sourced from global manufacturers, including: Pseudovac (polyvalent vaccine), Fluvaxin (influenza prevention), Rovatinex (urolithiasis treatment), Akineton (Parkinson's disease treatment), FATOL Riemser (anti-tuberculosis drugs), Provag (probiotic for vaginal dysbacteriosis), SiderAl (iron-deficient anemia treatment), Gestalis (prenatal vitamins), Dapson Fatol (autoimmune disease treatment), and DiCappa (osteoporosis prevention). The company operates from Slough and serves markets across Europe and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Pseudovac vaccine A unique polyvalent vaccine used for prevention and treatment of Pseudomonas aeruginosa blue pus infection. Prescribed as both a preventive and therapeutic drug to create active resistance against infection and reduce risk of bacteremia and sepsis.
• Fluvaxin Highly effective influenza prevention solution designed for workplace wellness, providing total safety at minimum cost to help employees stay healthy throughout the year.
• Rovatinex Urolithiasis treatment that removes gravel and fine concrements through spasmolytic, diuretic, antimicrobial and anti-inflammatory effects of natural terpenes.
• Akineton Parkinson's disease treatment (INN Biperiden) included in standard drug lists and Federal Medical Manual for administration of drugs.
• FATOL Riemser anti-tuberculosis drug portfolio Anti-tuberculosis drug portfolio from FATOL Riemser Co., including treatments for resistant strains. Products are GMP compliant with high-quality materials and equipment.
• Provag Peroral probiotic used to treat and prevent vaginal dysbacteriosis, addressing health problems, discomfort and related conditions caused by dysfunctional vaginal micro flora.
• SiderAl Innovative iron-deficient anemia treatment, ranked number one in iron-bearing drug sales in Italy. Has no strong side effects and can be administered during pregnancy and breast feeding.
• Gestalis Unique multivitamin set for pregnant and nursing mothers containing vitamin K, selenium, liposome iron, and herbal docosahexaenoic acid extracted from algae.
• Dapson Fatol Autoimmune disease treatment (INN Dapson) used for conditions including inflammatory articular rheumatism, multiple sclerosis, type I diabetes, regional enteritis, ulcerative colitis, and pemphigus.
• DiCappa Osteoporosis prevention and correction treatment containing vitamins K2 and D3. Ensures optimized mineralization of osseous tissue without risk of arterial vessel calcification, suitable for patients with various osteoporosis manifestations.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Clinigen Group: UK-headquartered specialty pharmaceutical distributor and access provider supplying unlicensed, niche, and hard-to-source medicines globally. Directly comparable in specialty pharma access/distribution model and geographic reach to Zydex.
• Trident Pharmaceuticals: UK-based specialty pharmaceutical distributor focused on parallel imports and unlicensed medicines. Comparable niche competitor in the same secondary-market pharmaceutical distribution category as Zydex.
• Mawdsley-Brooks: UK-based pharmaceutical wholesaler and distributor with a similar specialty and parallel-import focus, serving healthcare organisations across multiple therapeutic areas. Closely comparable in business model, customer base, and product mix to Zydex.

Broad incumbents

• Alliance Healthcare: One of the largest pharmaceutical wholesalers and distributors in the UK and Europe (part of Walgreens Boots Alliance). Operates across the full pharma distribution value chain and represents the scaled incumbent against which niche players like Zydex compete.
• Phoenix Group: European pharmaceutical wholesale and retail group operating across multiple countries. Comparable as a broad-line incumbent in the same pharma distribution space, with overlapping customer types (pharmacies, hospitals) to Zydex.
• AAH Pharmaceuticals: Major UK pharmaceutical wholesaler serving community pharmacies, hospitals, and dispensing doctors. Represents a full-line incumbent competitor with overlapping downstream customer base to Zydex's enterprise healthcare buyers.
• Ethypharm: International specialty pharmaceutical company active in distribution, licensing, and supply of niche medicines across Europe and emerging markets. Comparable as a specialty pharma intermediary with cross-border reach similar to Zydex.

Regional players

• Drug Houses of Australia (DHA): Australian pharmaceutical wholesaler and distributor serving hospital and retail channels. Comparable in wholesale distribution model and product breadth but operates in Asia-Pacific rather than UK/Europe like Zydex.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zydex